The images created during the daily scientific and medical endeavours at the Champalimaud Foundation can be as beautiful and compelling as any work of art. To the untrained eye, these images might also appear baffling, but, if you know what you’re looking at, they may just reveal information that can spark discoveries, contribute to the improvement of patient quality of life and maybe even alter our understanding of reality.

Join us for the FAITH Project's closing conference, where we'll delve into the crucial intersection of the FAITH AI technology and trials as well as key issues of mental health, survivorship in cancer and lessons learnt.

Description

Nuno Prego Ramos, co-founder and CEO of CellmAbs, will share the journey of CellmAbs, from it's early days starting with an initial technology from NOVA University to becoming a pioneering force in cancer therapy innovation.

In this talk, we will hear about the strategic decisions, challenges and breakthroughs that propelled the company to its selling the assets to the pharmaceutical giant, BioNTech.

“When I explain to my friends and family the rigorous regulations in place to ensure ethical treatment of experimental animals, they seem surprised.
 
It is important that people know that researchers that use animals are obliged to have appropriate qualifications and training. That scientific projects are evaluated to ensure that the use of animals is needed, beneficial and that no unnecessary harm is inflicted. And that the highest standards of housing conditions must be provided by the facilities where animals are housed.
 

A study published in mid-April in the journal Nature Communications by Leopoldo Petreanu and his team, from the Cortical Circuits lab at Champalimaud Research, concludes that sensory processing by the visual cortex’s is not purely visual. More to the point, the study shows that, right from the early stages of sensory processing, the visual cortex integrates information from other sensory modalities, such as sounds.

Do you know all about Non-Melanoma Skin Cancer (NMSC)?

We are thrilled to announce that the registrations for the NMSC Symposium “Non-Melanoma Skin Cancer. What do we know?”, hosted by the Champalimaud Foundation on the 7th of June, are now open!

This event will be a fusion of clinical expertise and research advancements, bringing together experts and healthcare professionals to discuss the latest research findings and clinical developments in the diagnosis and treatment of Non-Melanoma Skin Cancer.

There are varying degrees in the response of a cancerous tumour to a treatment. A complete response corresponds to the disappearance of all detectable signs of cancer in the body, while a partial or incomplete response is a decrease in the size of the tumour or in the amount of cancer in the body. To be considered a partial response, the measurable size of the tumor has to be reduced by at least 30% to 50% due to the treatment. 

The word “cerebellum” means “little brain”, despite the fact that it holds more than half the brain’s neurons. It is essential for coordinating movements and balance, helping you perform everyday tasks smoothly, like walking down a crowded street, or playing sports. It is also crucial for the learning process that allows you to associate sensory cues with specific actions.

A strategy called Watch & Wait (W&W) has increasingly been used, including at the Champalimaud Foundation, to avoid surgery and its associated complications, in a selected group of patients  whose tumours become undetectable after chemoradiotherapy. In terms of the local tumour control, it has been shown to be as safe to operate them later – if ever their tumour gives any sign of coming back – as to operate them immediately after chemoradiotherapy treatment.